Knopp Neurosciences Donates Phase III Dex Data to PRO-ACT

Exciting Breaking News! Knopp Neurosciences Inc. has agreed to donate a portion of the de-identified patient data from the recent Phase III clinical trial of dexpramipexole (Dex) in ALS to the PRO-ACT database (www.ALSDatabase.org). Under the agreement, Knopp will donate the clinical data collected from the 468 placebo subjects that participated in the trial to PRO-ACT. In addition, Knopp plans to donate the data from the treatment-arm group of the Phase III trial to PRO-ACT after all studies of Dex in ALS are complete. Currently, PRO-ACT consists of over 8,500 ALS patient records from 17 completed Phase II and Phase III clinical trials conducted by companies including Teva, Novartis, Sanofi, and Regeneron. The addition of these new data will push the number of ALS patient records to over 9,000 in PRO-ACT! If you haven’t checked out PRO-ACT, now is the time! There are many outstanding research questions that these new data can help address. In April, Prize4Life and the Neurological Clinical Research Institute (NCRI) were awarded the 2013 Best Practices Award in the Clinical & Health IT category from Bio-IT World for PRO-ACT. PRO-ACT is a collaboration between Prize4Life, the Northeast ALS Consortium (NEALS), and the NCRI at Massachusetts General Hospital, and is supported by funding from the ALS Therapy Alliance.

Exciting Breaking News! Knopp Neurosciences Inc. has agreed to donate a portion of the de-identified patient data from the recent Phase III clinical trial of dexpramipexole (Dex) in ALS to the PRO-ACT database (www.ALSDatabase.org). Under the agreement, Knopp will donate the clinical data collected from the 468 placebo subjects that participated in the trial to PRO-ACT. In addition, Knopp plans to donate the data from the treatment-arm group of the Phase III trial to PRO-ACT after all studies of Dex in ALS are complete. Currently, PRO-ACT consists of over 8,500 ALS patient records from 17 completed Phase II and Phase III clinical trials conducted by companies including Teva, Novartis, Sanofi, and Regeneron. The addition of these new data will push the number of ALS patient records to over 9,000 in PRO-ACT! If you haven’t checked out PRO-ACT, now is the time! There are many outstanding research questions that these new data can help address. In April, Prize4Life and the Neurological Clinical Research Institute (NCRI) were awarded the 2013 Best Practices Award in the Clinical & Health IT category from Bio-IT World for PRO-ACT. PRO-ACT is a collaboration between Prize4Life, the Northeast ALS Consortium (NEALS), and the NCRI at Massachusetts General Hospital, and is supported by funding from the ALS Therapy Alliance.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail